Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Barclays analyst Emily Field maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations ... that may be related to dosing errors ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The authority notes that six such products are currently being sold through websites, social media, and other informal ...

While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining ... that may be related to dosing errors associated with compounded injectable semaglutide products ...